PRESS RELEASES

Date Title and Summary View
Toggle Summary Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS
View HTML
Toggle Summary Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer, announces the independent data safety monitoring board (DSMB) recently concluded that, from a safety perspective, the Company's NASH-CX trial sh...
View HTML
Toggle Summary Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial
View HTML
Toggle Summary Autoimmune Disease Patent Granted to Galectin Therapeutics
NORCROSS, Ga., June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." The patent's principal claims cover me...
View HTML
Toggle Summary Autoimmune Disease Patent Granted to Galectin Therapeutics
NORCROSS, Ga. , June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of Novel Carbohydrate Drug for Treatment of
View HTML
Toggle Summary Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update View HTML
Toggle Summary Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2017. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Sec...
View HTML
Toggle Summary Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver Line, an online community and publication on liver health and liver disease. ...
View HTML
Toggle Summary Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received a Decision to Grant from the Japanese Patent Office for its patent application for "Composition...
View HTML
Toggle Summary Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today a...
View HTML